600422 昆药集团
已收盘 12-31 15:00:00
资讯
新帖
简况
昆药集团(600422)披露董事会授权管理制度修订,12月31日股价上涨0.48%
证券之星 · 2025-12-31
昆药集团(600422)披露董事会授权管理制度修订,12月31日股价上涨0.48%
昆药集团最新公告:选举贺明为职工代表董事
证券之星 · 2025-12-29
昆药集团最新公告:选举贺明为职工代表董事
每周股票复盘:昆药集团(600422)拟增董事会至15人
证券之星 · 2025-12-28
每周股票复盘:昆药集团(600422)拟增董事会至15人
昆药集团(600422)披露拟增补董事会成员并调整公司治理结构,12月22日股价上涨0.24%
证券之星 · 2025-12-22
昆药集团(600422)披露拟增补董事会成员并调整公司治理结构,12月22日股价上涨0.24%
昆药集团(600422)披露召开2025年第五次临时股东大会通知,12月09日股价下跌0.91%
证券之星 · 2025-12-09
昆药集团(600422)披露召开2025年第五次临时股东大会通知,12月09日股价下跌0.91%
昆药集团前三季度净利2.69亿元,同比下降39.42%
北京商报 · 2025-10-24
昆药集团前三季度净利2.69亿元,同比下降39.42%
昆药集团(600422)披露公司2025年第四次临时股东大会决议公告,10月10日股价上涨0.57%
证券之星 · 2025-10-10
昆药集团(600422)披露公司2025年第四次临时股东大会决议公告,10月10日股价上涨0.57%
每周股票复盘:昆药集团(600422)渠道改革与集采进展
证券之星 · 2025-08-24
每周股票复盘:昆药集团(600422)渠道改革与集采进展
昆药集团:8月17日投资者关系活动记录,包括知名机构淡水泉,汉和资本的多家机构参与
证券之星 · 2025-08-20
昆药集团:8月17日投资者关系活动记录,包括知名机构淡水泉,汉和资本的多家机构参与
昆药集团股价微跌0.68% 半年度营收33.51亿元
金融界 · 2025-08-19
昆药集团股价微跌0.68% 半年度营收33.51亿元
中报“增收不增利”的华润三九:CHC业务“失速”,“三费”大增挤压利润,昆药集团营利双降“添堵”
证券之星 · 2025-08-19
中报“增收不增利”的华润三九:CHC业务“失速”,“三费”大增挤压利润,昆药集团营利双降“添堵”
昆药集团股价小幅上扬 开源证券给予买入评级
金融界 · 2025-08-18
昆药集团股价小幅上扬 开源证券给予买入评级
东吴证券-昆药集团-600422-2025年半年报点评:多重因素下业绩承压,渠道改革持续蓄能-250818
市场资讯 · 2025-08-18
东吴证券-昆药集团-600422-2025年半年报点评:多重因素下业绩承压,渠道改革持续蓄能-250818
国金证券:给予昆药集团增持评级
证券之星 · 2025-08-17
国金证券:给予昆药集团增持评级
昆药集团(600422)2025年中报简析:净利润减26.88%
证券之星 · 2025-08-17
昆药集团(600422)2025年中报简析:净利润减26.88%
每周股票复盘:昆药集团(600422)股东户数增加,上半年营收下降11.68%
证券之星 · 2025-08-17
每周股票复盘:昆药集团(600422)股东户数增加,上半年营收下降11.68%
华润医药(03320):昆药集团上半年归母净利约1.98亿元,同比减少26.88%
智通财经 · 2025-08-15
华润医药(03320):昆药集团上半年归母净利约1.98亿元,同比减少26.88%
图解昆药集团中报:第二季度单季净利润同比减22.96%
证券之星 · 2025-08-15
图解昆药集团中报:第二季度单季净利润同比减22.96%
昆药集团股份有限公司发布压片机采购公告
DoNews · 2025-08-09
昆药集团股份有限公司发布压片机采购公告
松金市场咨询(北京)有限公司中标昆药集团调研项目
DoNews · 2025-08-08
松金市场咨询(北京)有限公司中标昆药集团调研项目
加载更多
公司概况
公司名称:
昆药集团股份有限公司
所属行业:
医药制造业
上市日期:
2000-12-06
主营业务:
昆药集团股份有限公司的主营业务是药物研发、生产及销售、医药流通及大健康产业。公司的主要产品是昆药血塞通系列、蒿甲醚系列,华润圣火理洫王血塞通软胶囊,昆中药参苓健脾胃颗粒、舒肝颗粒、香砂平胃颗粒,贝克诺顿阿法骨化醇软胶囊、玻璃酸钠注射液、医药流通商业、健康产业、国际化医疗健康服务。公司荣获由证券时报主办的第十六届“中国上市公司投资者关系管理天马奖”。
发行价格:
10.22
{"stockData":{"symbol":"600422","market":"SH","secType":"STK","nameCN":"昆药集团","latestPrice":12.56,"timestamp":1767164401000,"preClose":12.5,"halted":0,"volume":2996386,"delay":0,"changeRate":0.0048,"floatShares":757000000,"shares":757000000,"eps":0.7003,"marketStatus":"已收盘","change":0.06,"latestTime":"12-31 15:00:00","open":12.55,"high":12.59,"low":12.49,"amount":37587200,"amplitude":0.008,"askPrice":12.56,"askSize":815,"bidPrice":12.55,"bidSize":116,"shortable":0,"etf":0,"ttmEps":0.7003,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767576600000},"marketStatusCode":5,"adr":0,"adjPreClose":12.5,"symbolType":"stock","openAndCloseTimeList":[[1767144600000,1767151800000],[1767157200000,1767164400000]],"highLimit":13.75,"lowLimit":11.25,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":756975757,"isCdr":false,"pbRate":1.79,"roa":"--","peRate":17.935171,"roe":"5.07%","epsLYR":0.86,"committee":-0.05718,"marketValue":9508000000,"turnoverRate":0.004,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-01-05。","floatMarketCap":9508000000},"requestUrl":"/m/hq/s/600422","defaultTab":"news","newsList":[{"id":"2595778311","title":"昆药集团(600422)披露董事会授权管理制度修订,12月31日股价上涨0.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595778311","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595778311?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:56","pubTimestamp":1767174974,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘,昆药集团报收于12.56元,较前一交易日上涨0.48%,最新总市值为95.08亿元。该股当日开盘12.55元,最高12.59元,最低12.49元,成交额达3758.72万元,换手率为0.4%。近日,昆药集团股份有限公司发布《董事会授权管理制度》,明确董事会可将部分职权授予董事长、总裁等授权对象,但法定职权和需股东会决定事项不可授权。制度自董事会审议通过后生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100033105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0060","600422","BK0239"],"gpt_icon":0},{"id":"2595478265","title":"昆药集团最新公告:选举贺明为职工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2595478265","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595478265?lang=zh_cn&edition=full","pubTime":"2025-12-29 19:30","pubTimestamp":1767007814,"startTime":"0","endTime":"0","summary":"昆药集团(600422.SH)公告称,公司于2025年12月29日召开2025年第五次临时股东大会,审议通过《关于修订的议案》。根据新修订的《公司章程》,公司董事会由15名董事组成,其中包括1名职工代表董事。近日,公司召开第五届职工代表大会第五次会议,选举贺明为公司十一届董事会职工代表董事,任期自2025年第五次临时股东大会审议通过《关于修订的议案》之日起至公司十一届董事会任期届满之日止。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900030846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0060","BK0028","600422"],"gpt_icon":0},{"id":"2594524753","title":"每周股票复盘:昆药集团(600422)拟增董事会至15人","url":"https://stock-news.laohu8.com/highlight/detail?id=2594524753","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594524753?lang=zh_cn&edition=full","pubTime":"2025-12-28 04:58","pubTimestamp":1766869089,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,昆药集团报收于12.66元,较上周的12.46元上涨1.61%。本周,昆药集团12月26日盘中最高价报12.69元。本周关注点公司公告汇总:昆药集团拟将董事会席位由9人增至15人,取消监事会。公司公告汇总昆药集团召开2025年第五次临时股东大会,审议2026年日常关联交易预估、修订公司章程、股东大会议事规则、董事会议事规则、独立董事工作制度,并增补董事会成员。本次担保在2025年度预计担保额度内,已履行董事会及股东大会审批程序。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600422","BK0028","BK0188","BK0060","BK0239"],"gpt_icon":0},{"id":"2593435200","title":"昆药集团(600422)披露拟增补董事会成员并调整公司治理结构,12月22日股价上涨0.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593435200","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593435200?lang=zh_cn&edition=full","pubTime":"2025-12-22 22:56","pubTimestamp":1766415405,"startTime":"0","endTime":"0","summary":"截至2025年12月22日收盘,昆药集团报收于12.49元,较前一交易日上涨0.24%,最新总市值为94.55亿元。该股当日开盘12.47元,最高12.53元,最低12.42元,成交额达4966.33万元,换手率为0.53%。近日,昆药集团发布2025年第五次临时股东大会会议资料,宣布将审议多项公司治理相关议案。公告显示,公司拟将董事会席位由9人增至15人,同时取消监事会,并强化董事会审计与风险控制委员会的职能。此外,会议还将审议2026年日常关联交易预估事项,预计关联交易总额为7.8亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200035779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600422","BK0060","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2590342383","title":"昆药集团(600422)披露召开2025年第五次临时股东大会通知,12月09日股价下跌0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590342383","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590342383?lang=zh_cn&edition=full","pubTime":"2025-12-09 22:21","pubTimestamp":1765290090,"startTime":"0","endTime":"0","summary":"截至2025年12月9日收盘,昆药集团报收于13.01元,较前一交易日下跌0.91%,最新总市值为98.48亿元。近日,昆药集团发布关于召开2025年第五次临时股东大会的通知。公告显示,公司将于2025年12月29日召开2025年第五次临时股东大会,会议将采用现场投票与网络投票相结合的方式进行,网络投票通过上海证券交易所系统开展。关联股东华润三九需回避表决日常关联交易相关议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900040794.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0239","BK0060","600422"],"gpt_icon":0},{"id":"2577517185","title":"昆药集团前三季度净利2.69亿元,同比下降39.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577517185","media":"北京商报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577517185?lang=zh_cn&edition=full","pubTime":"2025-10-24 21:55","pubTimestamp":1761314100,"startTime":"0","endTime":"0","summary":"北京商报讯(记者丁宁)10月24日晚间,昆药集团(600422)发布2025年三季报显示,公司前三季度营业收入47.51亿元,同比下降18.08%;归属净利润2.69亿元,同比下降39.42%。 针对净利变动的原因,昆药集团表示,主要系公司持续推进模式再造与渠道变革向深水区突破,渠道动能转换期内,销售端面临阶段性承压,叠加全国中成药集采扩围续约执行进度晚于预期、零售药店终端整合等多重因素影响所致。(文章来源:北京商报)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-24/doc-infuzhch6700418.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-24/doc-infuzhch6700418.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","BK0060","BK0028","600422","BK0239"],"gpt_icon":0},{"id":"2574177409","title":"昆药集团(600422)披露公司2025年第四次临时股东大会决议公告,10月10日股价上涨0.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574177409","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574177409?lang=zh_cn&edition=full","pubTime":"2025-10-10 22:47","pubTimestamp":1760107638,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘,昆药集团报收于14.08元,较前一交易日上涨0.57%,最新总市值为106.58亿元。近日,昆药集团发布2025年第四次临时股东大会决议公告。公告显示,本次股东大会于2025年10月10日在云南省昆明市国家高新技术开发区科医路166号召开,由董事长吴文多主持。出席会议的股东和代理人共948人,代表有表决权股份总数316,628,271股,占公司有表决权股份总数的41.8280%。本次会议无否决议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101000039758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0188","600422","BK0028"],"gpt_icon":0},{"id":"2561589752","title":"每周股票复盘:昆药集团(600422)渠道改革与集采进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2561589752","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561589752?lang=zh_cn&edition=full","pubTime":"2025-08-24 04:52","pubTimestamp":1755982331,"startTime":"0","endTime":"0","summary":"截至2025年8月22日收盘,昆药集团报收于14.39元,较上周的14.57元下跌1.24%。本周,昆药集团8月18日盘中最高价报14.79元。昆药集团当前最新总市值108.93亿元,在中药板块市值排名24/67,在两市A股市值排名1739/5152。报告期内,血塞通口服系列及注射用血塞通冻干产品在二季度恢复同环比增长。自昆药集团加入华润三九以后,公司近 2年在渠道建设、媒介品牌等领域推进多项改革,销售费用已随公司收入体量、业务结构及产品布局有所下降。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082400000890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600422","BK0060","BK0028","BK0239"],"gpt_icon":0},{"id":"2560103185","title":"昆药集团:8月17日投资者关系活动记录,包括知名机构淡水泉,汉和资本的多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2560103185","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560103185?lang=zh_cn&edition=full","pubTime":"2025-08-20 20:04","pubTimestamp":1755691460,"startTime":"0","endTime":"0","summary":"报告期内,血塞通口服系列及注射用血塞通冻干产品在二季度恢复同环比增长。湖北、江西两省自 4月 30日起官宣执行中选结果,其余多数省份计划在 5-7月期间执行,截至目前已有 20余省份发文公布执行时间。答:随着理洫王、络泰营销团队的全面整合,777品牌在 7月启动全面融合,此后,华润圣火将逐步转型为生产单元,专注于专业化的生产建设。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082000039679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600422","BK0239","BK0028","BK0188","BK0060"],"gpt_icon":0},{"id":"2560113871","title":"昆药集团股价微跌0.68% 半年度营收33.51亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2560113871","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560113871?lang=zh_cn&edition=full","pubTime":"2025-08-19 23:27","pubTimestamp":1755617277,"startTime":"0","endTime":"0","summary":"昆药集团股价报14.59元,较前一交易日下跌0.68%。盘中最高触及14.78元,最低下探14.57元,成交额达2.99亿元。昆药集团是专注于植物药和天然药物研发的医药企业,主要产品包括血塞通系列、青蒿素类药品等。昆药集团近日发布2025年半年度报告,报告显示公司实现营业收入33.51亿元,归母净利润1.98亿元。公司表示二季度运营状况较一季度有所好转,血塞通系列产品销量恢复增长。在全球化布局方面,公司血塞通制剂已获15个国家准入资格。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/19232752549244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["600422"],"gpt_icon":0},{"id":"2560168937","title":"中报“增收不增利”的华润三九:CHC业务“失速”,“三费”大增挤压利润,昆药集团营利双降“添堵”","url":"https://stock-news.laohu8.com/highlight/detail?id=2560168937","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560168937?lang=zh_cn&edition=full","pubTime":"2025-08-19 14:50","pubTimestamp":1755586250,"startTime":"0","endTime":"0","summary":"这是华润三九2021年以来首次出现半年度净利润下滑。华润三九表示,净利润有所下降主要由于2024年上半年高基数的影响。证券之星注意到,华润三九费用开支的增加也挤压利润空间。由于CHC业务大幅下滑,拉低整体增速。需要注意的是,被华润三九收购后,昆药集团的营收近乎原地踏步。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025081900020042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0012","BK0188","BK0028","BK0196","000999","BK0010","600422","BK0185","BK0183","BK0175"],"gpt_icon":0},{"id":"2560900553","title":"昆药集团股价小幅上扬 开源证券给予买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2560900553","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560900553?lang=zh_cn&edition=full","pubTime":"2025-08-18 20:41","pubTimestamp":1755520904,"startTime":"0","endTime":"0","summary":"截至2025年8月18日收盘,昆药集团股价报14.69元,较前一交易日上涨0.82%,成交额达2.97亿元。昆药集团主营业务涵盖中药研发、生产和销售,产品包括血塞通系列、天麻素系列等。公司近年来持续推进渠道改革,并积极参与全国药品集采。开源证券发布研报称,给予昆药集团买入评级,认为公司渠道改革进入关键阶段,2025年下半年集采速度有望加快。风险提示:市场及政策变化风险、产品销售不及预期、新品研发不及预期。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/18204152512131.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["600422","161027"],"gpt_icon":0},{"id":"2560905388","title":"东吴证券-昆药集团-600422-2025年半年报点评:多重因素下业绩承压,渠道改革持续蓄能-250818","url":"https://stock-news.laohu8.com/highlight/detail?id=2560905388","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560905388?lang=zh_cn&edition=full","pubTime":"2025-08-18 17:26","pubTimestamp":1755509160,"startTime":"0","endTime":"0","summary":"2025年单Q2季度,公司实现收入17.43亿元,归母净利润1.08亿元,扣非归母净利润0.79亿元,环比Q1有所改善。对于集采中选产品,公司进一步拓展销售渠道,提升在各级医疗机构的覆盖率,随着下半年集采执行的推进,公司三七血塞通系列产品有望放量加速。2025年下半年,集采中标产品有望放量,随着渠道改革逐步稳定,下半年业绩有望环比改善,维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-08-18/doc-infmkyty9883691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0276","BK0009","601555","BK0183","BK0239","600422","BK0028","BK0012","BK0188","BK0060"],"gpt_icon":0},{"id":"2560392153","title":"国金证券:给予昆药集团增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2560392153","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560392153?lang=zh_cn&edition=full","pubTime":"2025-08-17 13:20","pubTimestamp":1755408026,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕,王奔奔近期对昆药集团进行研究并发布了研究报告《集采执行晚于预期,下半年趋势有望向好》,给予昆药集团增持评级。 昆药集团 2025年8月15日,公司发布2025年半年报。最新盈利预测明细如下:该股最近90天内共有4家机构给出评级,买入评级3家,增持评级1家;过去90天内机构目标均价为18.9。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081700004032.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600422"],"gpt_icon":0},{"id":"2560926617","title":"昆药集团(600422)2025年中报简析:净利润减26.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2560926617","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560926617?lang=zh_cn&edition=full","pubTime":"2025-08-17 06:01","pubTimestamp":1755381686,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期昆药集团发布2025年中报。根据财报显示,昆药集团净利润减26.88%。截至本报告期末,公司营业总收入33.51亿元,同比下降11.68%,归母净利润1.98亿元,同比下降26.88%。管理费用变动幅度为8.04%,原因:管理职能细化。持有昆药集团最多的基金为富国研究精选灵活配置混合A,目前规模为6.99亿元,最新净值2.867,较上一交易日上涨0.88%,近一年上涨21.23%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081700001009.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600422"],"gpt_icon":0},{"id":"2560925074","title":"每周股票复盘:昆药集团(600422)股东户数增加,上半年营收下降11.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2560925074","media":"证券之星","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560925074?lang=zh_cn&edition=full","pubTime":"2025-08-17 04:39","pubTimestamp":1755376751,"startTime":"0","endTime":"0","summary":"截至2025年8月15日收盘,昆药集团报收于14.57元,较上周的14.57元上涨0.0%。本周,昆药集团8月12日盘中最高价报14.85元。本周关注点股本股东变化:截至2025年6月30日股东户数为3.94万户,较3月31日增加2665户业绩披露要点:2025年中报显示主营收入33.51亿元,同比下降11.68%公司公告汇总:监事会审议通过2025年半年度报告及聘请2025年度审计机构的议案股本股东变化近日昆药集团披露,截至2025年6月30日公司股东户数为3.94万户,较3月31日增加2665.0户,增幅为7.26%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081700000770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600422"],"gpt_icon":0},{"id":"2559591697","title":"华润医药(03320):昆药集团上半年归母净利约1.98亿元,同比减少26.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2559591697","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559591697?lang=zh_cn&edition=full","pubTime":"2025-08-15 18:47","pubTimestamp":1755254856,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华润医药(03320)公布昆药集团2025年上半年业绩,营业总收入约33.51亿元,同比减少11.68%;上市公司股东应占净利润约1.98亿元,同比减少26.88%;每股基本盈利0.26元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1330295.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600422","03320","BK0028","BK1570","BK0188","BK0060","BK0239","BK1191"],"gpt_icon":0},{"id":"2559915266","title":"图解昆药集团中报:第二季度单季净利润同比减22.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2559915266","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559915266?lang=zh_cn&edition=full","pubTime":"2025-08-15 18:15","pubTimestamp":1755252910,"startTime":"0","endTime":"0","summary":"证券之星消息,昆药集团2025年中报显示,公司主营收入33.51亿元,同比下降11.68%;归母净利润1.98亿元,同比下降26.88%;扣非净利润1.51亿元,同比下降5.57%;其中2025年第二季度,公司单季度主营收入17.43亿元,同比下降6.68%;单季度归母净利润1.08亿元,同比下降22.96%;单季度扣非净利润7904.0万元,同比上升67.7%;负债率46.51%,投资收益-69.46万元,财务费用2310.89万元,毛利率39.85%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081500036589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600422"],"gpt_icon":0},{"id":"2558025195","title":"昆药集团股份有限公司发布压片机采购公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2558025195","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558025195?lang=zh_cn&edition=full","pubTime":"2025-08-09 23:31","pubTimestamp":1754753462,"startTime":"0","endTime":"0","summary":"天眼查App显示,昆药集团股份有限公司于2025年08月08日在广东省发布《昆药集团(珠海横琴)科技有限公司实验室项目-压片机采购公告》。本次采购内容为实验用单冲压片机一台,由采购人昆药集团股份有限公司直接发起,采购项目编号为SJCGXY202508080014,采购内容和范围包括实验用单冲压片机一台,指导甲方安装,乙方自主调试。采购文件获取、响应文件提交及相关流程均通过华润守正采购交易平台线上完成,报价截止时间为2025年08月13日12:00(北京时间)。公告类型为招标公告,目前尚未公布中标供应商及中标金额信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080923321294d9ba02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080923321294d9ba02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","BK0060","600422","BK0188","BK0239"],"gpt_icon":0},{"id":"2557273075","title":"松金市场咨询(北京)有限公司中标昆药集团调研项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2557273075","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557273075?lang=zh_cn&edition=full","pubTime":"2025-08-08 21:06","pubTimestamp":1754658363,"startTime":"0","endTime":"0","summary":"天眼查App显示,2025年08月07日,昆药集团股份有限公司发布零售终端调研体系建构项目询价结果公告。公告显示,项目成交供应商为松金市场咨询(北京)有限公司。此次采购属于询价结果公告类型,采购人明确为昆药集团股份有限公司。详细信息未包含中标金额及其他补充内容。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080821071994d7bde6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080821071994d7bde6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0060","BK0188","BK0028","600422","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767454241306,"stockEarnings":[{"period":"1week","weight":0.0064},{"period":"1month","weight":-0.0499},{"period":"3month","weight":-0.1003},{"period":"6month","weight":-0.1053},{"period":"1year","weight":-0.1912},{"period":"ytd","weight":-0.1912}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0222},{"period":"6month","weight":0.143},{"period":"1year","weight":0.1841},{"period":"ytd","weight":0.1841}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"昆药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"53735人(较上一季度增加36.50%)","perCapita":"14087股","listingDate":"2000-12-06","address":"云南省昆明市五华区国家高新技术产业开发区科医路166号","registeredCapital":"75697万元","survey":" 昆药集团股份有限公司的主营业务是药物研发、生产及销售、医药流通及大健康产业。公司的主要产品是昆药血塞通系列、蒿甲醚系列,华润圣火理洫王血塞通软胶囊,昆中药参苓健脾胃颗粒、舒肝颗粒、香砂平胃颗粒,贝克诺顿阿法骨化醇软胶囊、玻璃酸钠注射液、医药流通商业、健康产业、国际化医疗健康服务。公司荣获由证券时报主办的第十六届“中国上市公司投资者关系管理天马奖”。","listedPrice":10.22},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昆药集团(600422)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昆药集团(600422)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昆药集团,600422,昆药集团股票,昆药集团股票老虎,昆药集团股票老虎国际,昆药集团行情,昆药集团股票行情,昆药集团股价,昆药集团股市,昆药集团股票价格,昆药集团股票交易,昆药集团股票购买,昆药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昆药集团(600422)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昆药集团(600422)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}